Fig. 1From: Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trialTimeline and summarized study protocolV1, V2: First and second administration of Pembrolizumab at day 0 and day (d) 21. Q3w: every three weeks; EOT: end of treatment; RT: radiotherapy; PET: positron emission tomography; iv: intravenous; d: day; cMRI: cranium Magnet Resonance TomographyBack to article page